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Background:  
Heart failure is increasingly common, and characterised by frequent admissions to 
hospital. To try and reduce the risk of hospitalisation, techniques such as 
telemonitoring (TM) may have a role. We wanted to determine if TM in patients with 
newly diagnosed HF and ejection fraction <40% reduces the risk of re-admission or 
death from any cause in a “real world” setting. 
Methods: Retrospective study of 124 patients (78.2% male; 68.6±12.6 years) who 
underwent TM and 345 patients (68.5% male; 70.2±10.7 years) who underwent the 
usual-care (UC). The TM group were assessed daily by body weight, blood pressure 
and heart rate using electronic devices with automatic transfer of data to an online 
database. Follow-up was 12 months. 
Results: Death from any cause occurred in 8.1% of the TM-group and 19% of the UC-
group, p=0.002. There was no difference between the two groups in all-cause 
hospitalization, either in the number of subjects hospitalized (p=0.7) or in the 
number of admissions per patient (p=0.6). There was no difference in the number of 
heart failure-related readmissions per person between the two groups (p =0.5), but 
the number of days in hospital per person was higher in the UC group (p=0.03). Also, 
there were a significantly greater number of days alive and out of hospital for the 
patients in the TM-group compared with the UC-group (p=0.0001). 
Conclusions: TM is associated with lower any-cause mortality and also has the 
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potential to reduce number of days lost to hospitalization and death. 
Introduction 
Heart failure (HF) is a complex clinical syndrome, representing the final common 
pathway of many different pathological processes associated with high mortality 
rate and frequent hospital admissions (1-4). Over 50% of patients hospitalised with 
heart failure are readmitted within six months (5). To try and reduce the risk of 
hospitalisation, approaches such as telemonitoring (TM) have been introduced (6). 
Home TM involves the use of electronic devices and telecommunication 
technologies for the digital transmission of physiological and other disease –related 
data from patient’s home to a health care centre assisting in disease management. 
Recent meta-analyses suggest that TM may be associated with a better prognosis 
and reduced risk of hospitalisation in patients with HF (7-9).  
However, despite the encouraging results and the growing interest in TM among 
cardiologists, the use of TM has not been widely adopted, as many questions remain 
unanswered. A major obstacle to the widespread use of TM is the accurate 
identification of those patients with most to gain. We hypothesised that the patients 
at high risk, and hence potentially with most to benefit, were those who had 
recently been diagnosed with HF, and we therefore assessed the effects of TM in 
patients who were recently diagnosed HF with reduced ejection fraction (HFrEF) and 
had NYHA class II-III symptoms. 
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Methods 
Subjects 
In Kingston-upon-Hull, home-based TM for patients with chronic HF was adopted as 
a regional health service in 2009. Between 2009-2012, 453 patients were diagnosed 
during cardiology outpatient review with heart failure with reduced EF, based on ESC 
guidelines. Among these newly diagnosed HF patients, 124 accepted to receive the 
TM management and constitute the study group; while the remaining 329 patients, 
who refused the TM management,received the UC and represent the control group. 
Hospital records were retrospectively reviewed, and HF-related admissions data 
were collected. Additional information about the hospitalizations was gathered from 
individual’s general practitioners. All patients gave written consent for their clinical 
data to be anonymously used for research purposes. All patients gave written wide 
consent for their clinical data to be anonymously used for research purposes. 
Remote Telemonitoring System 
TM is performed with the use of the commercial system Motiva telemonitoring 
system (Philips Healthcare, Amsterdam, Netherlands). This includes a secure 
broadband home TV channel providing educational material, reminders of 
medication, health-related surveys and motivational messages to encourage the 
prescribed lifestyle regimen. Individuals were given automated devices for daily 
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measurements of BP, HR and weight at home; they were asked to obtain the 
measurements the same time of date, preferable in the morning half an hour after 
the intake of their tables. A nurse practitioner evaluated the measurements every 
day using a dedicated clinical user interface. Clinical alerts are dealt with by the HTM 
nurse calling the patient and then, if necessary, a clinical responder; either a 
community HF nurse with prescribing qualifications or a cardiologist if long-term 
changes in therapy are required.  
Patients in both groups were seen at a specialist HF clinic, by a cardiologist 
specialised in HF, for life-style advice and optimization of HF medication. The 
frequency of clinical follow-up was at the discretion of the HF team. The same 
cardiologists reviewed the patients in both groups. 
 
Statistical analysis 
The statistical analysis was performed using SPSS version 22.0. Baseline 
characteristics were expressed as mean and standard deviation or median and 
interquartile range. Continuous variables between the two groups were compared 
using the independent student’s t-test for normally distributed. Variables not 
normally distributed were logarithmically transformed before the analysis in order to 
assess normality and fulfil model assumptions. Categorical variables were analysed 
using the chi-square test. Survival analysis with a Kaplan-Meier curve was 
constructed for time to death. A p-value of <0.05 was accepted as statistically 
significant.   
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Results  
The patients were well matched for age, but the proportion of men was higher in the 
TM group. A higher proportion of the TM group had diabetes, but their NT-pro BNP 
tended to be lower, albeit not statistically significantly. The baseline clinical and 
demographics characteristics for the two groups are shown in Table 1. Finally, there 
were no differences between the two groups in the treatment with beta-blockers, 
ACE inhibitors/angiotensin receptor blockers and aldosterone antagonists. 
Mortality 
After 12 months of follow-up, all-cause mortality was significantly lower in the TM 
group than usual care (8.1% vs 18.8%; p=0.005). The Kaplan-Meier curves for 
mortality are shown in Figure 1. The mean number of days alive and out of hospital 
was significantly higher in TM group compared to UC group, 340.4 ± 96.9 vs. 341.7 ± 
78.4 respectively (p= 0.0001).  
All hospitalizations 
There was no significant difference between the two groups in all-cause 
hospitalization, either in the number of subjects hospitalized (63.7% in the TM group 
vs. 62% in the UC group, p=0.7) or in the number of admissions per patient (1.3 ± 1.7 
in TM group vs. 1.4±1.7, p=0.6). There was no difference in the number of days lost 
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to hospitalizations per patient (8.1 ± 12.8 days in TH group and 9.5 ± 17.3 in UC 
group, p=0.4).  
 
Heart failure-related hospitalizations 
Readmission for heart failure occurred in 11.3% in the TM group and 14.9% in the UC 
group, p=0.2. There was no difference in the number of heart failure-related 
readmissions per person between the two groups (0.2 ± 0.3 in UC vs. 0.2 ± 0.4 in TM, 
p =0.5), but the number of days in hospital per person was higher in the UC group 
(2.6 ± 8.8 in UC group vs. 1.3 ± 4.1 in TM group, p=0.03). 
Other cardiac hospitalizations 
The number of patients readmitted for any cardiac cause except HF was higher in UC 
group compared to TM group (22.8% vs. 13.7% respectively, p=0.02). The number of 
days in hospital per person was higher in UC group (2 ± 6) compared to TM group 
(0.9 ± 2.7), p=0.01. 
Renal failure hospitalizations 
Readmissions for renal failure was much more common in the UC group, 12.5% of 
subjects in UC group and 3.2% in TM group, p = 0.003.  
 
Discussion 
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In recent years, home TM has become an increasingly attractive option to 
supplement the care of patients with chronic HF.  Advances in data collection (such 
as simple automated sphygmomanometers) and transfer (Bluetooth; broadband; 
Wifi) allow for the regular, reliable and accurate communication of vital signs and 
symptoms from community-based patients.  Indeed, the data transferred by TM has 
become as reliable as those collected through face-to-face patient examination (10-
11). Home-based TM has the advantage of providing regular monitoring whilst 
overcoming potential geographic and logistical obstacles. However, despite all the 
advantages and the associated policy support, the use of TM has not been 
developed at the pace and scaled anticipated. Most studies show that TM programs 
are associated with a trend toward improvement in morbidity, although 
heterogeneity of results across studies has been noted (12). There are two main 
contributors to this heterogeneity. Firstly, the heterogeneity of study populations 
and secondly the heterogeneity in structure and function of TM service design. 
The main finding of this study is that TM can reduce mortality in patients who have 
been recently diagnosed with HF and have LV dysfunction. Moreover, the reduction 
in the mortality is achieved without an increase in the duration of time spent in 
hospital. On the contrary, TM reduced the number of days lost to death or 
hospitalization. Although, there was no reduction in readmissions for HF between 
home TM group and UC, there was a reduction in the number of days spent in the 
hospital. Similarly, while in both groups there was no reduction in the hospitalization 
rate for other cardiac cause, the TM group demonstrated a reduction in the duration 
of hospitalization. Finally, compared with UC, TM reduced the both the 
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hospitalization rate and duration of admission for renal failure. 
There are a number of possible mechanisms of action that may explain these 
findings. The reduced mortality in the TM patients may reflect the fact that TM 
improves patient heart failure knowledge and self-care behaviors. For example, 
participation in TM requires patients to weigh themselves on a daily basis, which is, 
in itself a recommendation for patients living with the condition (13). TM helps to 
educate patients on the importance of measuring other physiological parameters 
and taking their medication (14-15). Furthermore patients learn to recognize a 
change in themselves (such as increased weight), evaluate the symptoms, 
implement a treatment strategy in collaboration with the HF team (such as taking an 
extra diuretic dose), and evaluate the response to therapy. Several studies have 
shown that counseling and education of patients, promotion of patient compliance, 
daily weight measurements and easy access to a specialized HF team can reduce 
mortality in heart failure (16-17). Another aspect of our study that can be highlighted 
is the decrease in days in hospital for HF and for other cardiac causes. This probably 
reflects early detection of decomposition (18). TM most likely allowed for earlier 
detection of cardiovascular problem and more prompt and effective therapy through 
the bi-directional communication established between the patient and health care 
team.  
Our study extended the evidence base for TM for HF, in that we examined patients 
newly diagnosed with HF. To the best of our knowledge, this is the first study 
focusing on this population. In contrast with the other studies, which are 
randomized and have strict inclusion criteria, our study is based on real-world results 
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and a study population that represents the typical HF patient.  
Although current reports show that TM is a useful tool to keep patients out of 
hospital and prolong their survival, a lot of unsolved issues remain. There is a 
fundamental requirement for health services research to find out more about: the 
identification of patients that actually would benefit form TM and the mechanism of 
action of TM. 
In summary, TM has the potential to improve patient care in many ways. In patients 
newly diagnosed with HF and with reduced left ventricle systolic function, TM is 
associated with lower any-cause mortality. Furthermore TM has the potential to 
reduce the number of days lost to hospitalization and death. 
Limitations  
This study is based on the retrospective analysis of available data with its inherent 
limitations.  
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Table 1. Baseline subject characteristics of telemonitoring and usual care group. 
 
 Usual care 
(N= 329) 
Telemonitoring 
(N= 124) 
p-value 
Mean age, years (SD)   67.5 (10.6)  68.1 (12.7) 0.9 
Male (%) 224 (68.1)  97 (78,2) 0.03 
Primary cause of HF    
    Coronary Heart Disease, n (%) 185 (56.2)  70 (56.5) 0.2 
    Idiopathic dilated cardiomyopathy, n (%)   60 (18.2)  20 (21.9)  
    Hypertension, n (%)   26 (7.9)    4 (3.2)  
    Arrhythmia related, n (%)   16 (4.9)    5 (4)  
    Valve related, n (%)   12 (3.6)    8 (6.5)  
    Other, n (%)   30 (9.1)  17 (13.7)  
Co-morbidities    
     Chronic lung disease, n (%)    31 (9.4)  14 (11.3) 0.5 
     Stroke any, n (%)    21 (6.4)  11 (8.8) 0.4 
     Hypertension, n (%)    96 (29.2)  41 (33.1) 0.4 
     Diabetes mellitus, n (%)    85 (25.8)  49 (39.5) 0.004 
     Renal impairment, n (%)    29 (8.8)  10 (8) 0.9 
     Chronic or paroxysmal AF, n (%)    99 (30.1) 40 (32.2) 0.6 
Blood pressure (mmHg)    
     Systolic (mean, SD) 124.3 (22.8) 130.5 (24.1) 0.01 
     Diastolic (mean, SD)  76.3 (13.9)   77.3 (14.7) 0.5 
 16 
Serum creatinine (μmol/L)(mean, SD)  117.6 (62.2)  112.9 (47) 0.5 
NYHA class, n (%)    
     II  174 (52.9)    64 (51.6) 0.8 
     III  155 (47.1)    60 (48.4)  
Body mass index (mean, SD)    27.8 (5.6)    28 (6.3) 0.8 
NT-proBNP (pg/ml), (mean, SD) 4,102.4 (6279) 2,997.5 (3859.6) 0.06 
Haemoglobin (g/L) (mean, SD)      13.3 (1.8)     13.1 (2) 0.3 
Medication    
    ACE inhibitor or ARB, n (%)      260 (79)   103 (83) 0.3 
    Beta-blocker, n (%)      269 (81.7)   105 (84.6) 0.5 
    Aldosterone antagonist, n (%)      194 (58.9)     77 (62.1) 0.6 
 
 
 
 
Table 2. Study outcome: mortality and hospitalizations. 
 
 Usual care Telemonitoring p-value 
All-cause mortality   62 (18.8%)   10 (8.1%) 0.005 
Days alive 341.7± 78.4 320.4 ± 96.9 0.0001 
Days alive and out of hospital 319.8 ± 89.8  340.2 ± 64.7  0.0001 
Patients hospitalized for all-cause 204 (62%)   79 (63.7%) 0.7 
Hospitalizations for all cause /patient     1.4 ± 1.7     1.3 ± 1.7 0.6 
Days of hospitalizations for all-cause /patient     9.2 ± 17.3     8.1 ± 12.8 0.4 
Patients hospitalized for heart failure  49 (14.9%)   14 (11.3%) 0.2 
Heart failure Hospitalizations/patient    0.2 ± 0.3     0.2 ± 0.4 0.5 
Days of heart failure hospitalizations/patient    2.6 ± 8.8     1.3 ± 4.1 0.03 
Patients hospitalized for other cardiac cause  75 (22.8%)   17 (13.7%) 0.02 
Hospitalizations for other cardiac cause/patient      0.3 ± 1     0.3 ± 0.7 0.5 
Days of hospitalizations for other cardiac 
cause/patient 
    2.3 ± 6.2     0.9 ± 2.7 0.01 
Patients hospitalized for renal failure   41 (12.5%)      4 (3.2%) 0.003 
Hospitalizations for renal failure/patient      0.1 ± 0.3       0.04 ± 0.2 0.002 
 17 
Days of hospitalizations for renal failure/patient     0.3 ± 0.5      0.1 ± 1.5 0.01 
 
 
 
 
 
 
 
 
Figure 1.  Kaplan-Meier curve: mortality from all causes in the telemonitoring group 
and usual care group; p= 0.0001. 
 
 
 
 
 
 
 
 
 
 
 
